AstraZeneca And Ionis ATTR Ambitions Boosted
Efficacy of Eplontersen Maintained For 66 Weeks
The companies are hoping that new data on recently-filed eplontersen will boost the drug's chances of challenging Alnylam’s Amvuttra and Onpattro.
You may also be interested in...
The ATTRibute-CM study met its primary endpoint as well as key secondary endpoints, and the company plans to file for US FDA approval before the end of 2023.
AstraZeneca has bulked up its late-stage pipeline with an agreement for Ionis’s eplontersen which is in trials for two rare diseases, quelling some analysts’ fears about the scarcity of catalysts for next year.
The embattled German major is touting a promising mid-stage thrombolytic but the spotlight this week has continued to shine on its business model and high levels of debt.